Loading
Every dated change on the records linked to Lower-risk myelodysplastic syndromes, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
More patients achieved transfusion independence with a haemoglobin rise on luspatercept than on epoetin alfa; first-line approval in August 2023.
Imetelstat produced eight-week transfusion independence in significantly more patients than placebo; approved in June 2024.
A milestone in how this cancer is treated.
Luspatercept produced transfusion independence for eight weeks or longer in significantly more patients than placebo; approved in April 2020.
Median event-free survival 1,440 days with deferasirox against 1,091 days with placebo (hazard ratio 0.
A milestone in how this cancer is treated.